How do we improve diagnosis of atrial fibrillation globally to maximise our drug’s end-of-life sales?

We were tasked with helping our client, a world-leading pharmaceutical company, design screening programs capable of increasing the global diagnosis of atrial fibrillation.

We evaluated previous screening programs to see what had been most successful across the US, Canada and Europe, designing a global playbook of market-specific strategies and working with Global and affiliates to test these strategies and begin implementation.